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Abstract: Objective: To determine the
mechanism of action of Methotrexate and
Vepesid on the HEp-2 cells isolated from
human laryngeal cancer cells morphologically
and flow cytometrically (G1, G2, S and PI).
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Materials and Methods: The HEp-2
continuous cell line was used. Cultivation of
the cells was realized in EMEM medium
with 10% fetal bovine serum at an
atmosphere of 37ºC with 5% CO2. Six
different concentrations of Vepesid and
Methotrexate were prepared by diluting
with deionized water (5 µg/ml, 50 mg/ml,
500 µg/ml). The morphological and cell
cycle parameters of HEp-2 cells were
determined by inverted microscope and
flow cytometer respectively.

Introduction
One of the main objectives of modern chemotherapy
is to obtain better treatment with minimal toxic effects.
The drugs employed in oncology today are mostly
synthetic
(azacitine,
cytarabine,
fluorouracil,
mercaptopurine, methotrexate, thioguanine) and a minor
part is semi-synthetic (vincristine, vinblastine, paclitaxel).
The mechanism of action of the drugs in both groups is
basically on the intracellular enzymes and substrates, by
which they effect the cellular development. Because most
of the drugs produced synthetically are extremely toxic to
the cell, in recent years investigations have been focused
on drugs of plant origin (1).
Among the antimetabolic drugs, one of the most
important and widely used drugs is Methotrexate (MTX).
MTX is a chemical agent that acts by inhibiting the
enzyme dihydrofolic acid reductase, which catalyses the
conversion of folic acid to its active form folinic acid, by
binding to it (2, 3).
Vepesid is also a drug used in the treatment of cancer.

Results: In the morphological examination,
Vepesid was found to have a more significant
cytopathologic effect on the cells than
Methotrexate, whereas in the flow cytometric
examination, it was found that whilst
Methotrexate stopped the cells at the S and G2
phases, Vepesid did that only at the G1 phase.
Conclusion: Both the flow cytometric and cell
morphological analysis showed Vepesid to be
more effective than Methotrexate on HEp-2
cells. Results of studies conducted show the
mechanism of action of these drugs to be
dependent on the origin of the cell and on the
drug type.
Key Words: Cell cycle, Methotrexate, Vepesid,
HEp-2 cell, flow cytometer

It interferes with the multiplication of cancer cells and
slows or stops their growth and spread in the body.
Vepesid (etoposide), which is obtained from the plant
Podophylum peltatum, a plant alkaloid, is the semisynthetic derivative of podophylotoxin. Vepesid, like
other drugs in the group, exerts its effects by inhibiting
the synthesis of the DNA and RNA of the cells and thereby
inhibiting cell division (4).
Information regarding the mechanism of action and
pharmacological properties of MTX is abundant because it
has been in use various fields of oncology for a long time
(2, 5, 6). However vepesid, relative to MTX, is a very new
drug and has been introduced in the field of oncology only
recently. For this reason, information about its
mechanism of action on the different cancer cells is
relatively scant and contradictory (4, 7, 8). The number
of comparative studies about the therapeutic potency and
toxicity of this drug is also limited. In addition, we did not
come across any literature on the effects and toxicity of
these drugs on HEp-2 cells derived from human laryngeal
cancer cells.
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The effects of MTX and Vepesid on the HEp-2 cells
were investigated at concentrations of 5, 50, and 500
mg/ml in an EMEM culture medium containing 10% fetal
bovine serum. Also, as the control group, HEp-2 cells
were cultivated in media containing no anti-neoplastic
drug. After 48 hours of incubation, the cells were
examined morphologically with an inverted microscope.
Later the samples of cells growing in mono layers in the
culture plates were taken and washed with balanced
saline solution (PBS) and the cells were then covered with
a versen-trypsin solution (containing in 1L: 8 g NaCl, 0.2
g KCl, 2.37 g Na2HPO4*12 H2O, 0.2 g K2HPO4, 1 g
titriplex III (versen) 1.25 g trypsin (Sigma)). The culture
plates were kept at 37ºC for 5-10 minutes to allow the
cells to come off easily from the plates. Cells that were
separated by treatment with versen-trypsin solution were
centrifuged at 1000 rpm at +4ºC to remove the versentrypsin solution. Later, the cellular pellets that
precipitated at the bottom of the centrifuge tube were
prepared with the EMEM culture medium to contain
1,000,000 cells/ml and 12 x 75 ml tubes were each filled
with 100 ml portions of the resulting cell suspension for
flow cytometric analysis.

Figure 1 shows an example of how a population of
cycling cells might appear on a flow cytometer's data
display. The horizontal axis of the graph displays the
amount of DNA per cell, identified by relative, arbitrary
units. The vertical axis identifies the number of cells at
each amount of DNA.

—

Experiments were carried out on HEp-2 continuous
cell culture derived from human laryngeal cancer cells.
The HEp-2 continuous cell culture was obtained from the
Virology Department of the Ankara Refik Saydam Central
Hifzisihha Institute. In the preparation of the culture,
EMEM (Eagle’s Minimum Essential Medium) (Sigma) was
used as the medium and fetal bovine serum (Seromed)
was used as the growth factor in the medium at a ratio
of 10%. The cells were incubated at 37ºC in an
atmosphere of 5% CO2. All the culture plates were set to
contain a cell count of 100,000/ml.

—

Materials and Methods

was added and within 1-2 seconds 2 ml of the Coulter
DNA-prep stain (Coulter Electronics Hialeah, USA)
containing small amounts of Pi and RNA was added and
after gently stirring for approximately 20 minutes, it was
stored at room temperature in the dark. Later the
specimens were passed through the flow cytometer
equipment (Coulter, Epics XL, USA) for measurement.
The results obtained were evaluated using the Mplus AV
(version 3.01) computer program (Coulter Electronics,
USA). The DNA index was analyzed on the specimens
together with the chicken erythrocytes that contained the
n number of DNA. The DNA index was calculated by
dividing the peak G0/G1 of the specimen by the peak G0/G1
of the erythrocytes.

NUMBER OF CELLS

For these reasons, we investigated the effects of these
two anti-neoplastic drugs on cell growth and
development by analyzing the effects on both cell
morphology and the cell cycle parameters (G1, S, G2, and
the proliferation index) on HEp-2 cells using the inverted
microscope and the flow cytometer.
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Measuring of the cell cycle by the flow cytometer.

Results

DNA Analysis ( Determination of the Cell Cycle)

Morphological Analysis: The morphology of the
HEp-2 cells grown on culture media containing various
proportions of MTX and Vepesid were examined using the
inverted microscope.

100 ml of the Coulter DNA-prep LPR solution
(Coulter Electronics Health, USA), which promotes the
opening of the pores on the surface of cells in suspension

The cells in the control growth media at the end of the
48 hour incubation period were observed to have grown
with adhesion in a mono layer covering the entire surface
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In all culture media that contained MTX, cellular
adhesion and pathologic changes were observed in the
cells. Microscopic examination of the cells from the
culture media containing 5 µg/ml of MTX revealed, in
addition to the disruption of the cell membrane integrity,
findings such as granulation, nuclear enlargement and
rounding of cells. These morphological changes were
observed to be more pronounced with increasing
concentration (50 µg/ml and 500 µg/ml) of MTX.
In culture media that contained 5 µg/ml and 50 µg/ml
of Vepesid, morphologic changes similar to those of MTX
were found. These effects on the cells were observed to
be more striking for Vepesid than for MTX at the same
concentrations. In culture media that contained 500
µg/ml of Vepesid, however, disturbance in the adhesion
pattern, failure to grow in a mono layer, and
microscopically, cytopathologic changes like cell rounding
and significant nuclear enlargement were observed.
Flow Cytometric Analysis: These findings were
evaluated in two groups under cell cycle and proliferation
index.
Figure 2 shows the results of the comparison between
the effects of Vepesid and MTX on the cell cycle of the
HEp-2 cells and the effects on the control group. In the
figure, almost all the cells in the control group are seen
to exist in the G2 phase of the cell cycle. In media
containing MTX, most of the cells are in the S and a small
fraction in the G2 phase, whilst almost all those in media
containing Vepesid were in the G1 phase.
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The effects of Vepesid and Methotrexate on the cell cycle of
the HEp-2 cells.

In Figure 3, the proliferative indices of the culture
media containing MTX and Vepesid are shown together
with those of the controls. The proliferative index of
Vepesid is seen to be relatively lower than that of MTX.
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did not reveal cytopathologic changes such as granulation,
fusion, nuclear enlargement or cell rounding.
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Proliferation indices of HEp-2 cells in the media containing
Methotrexate and Vepesid.

Discussion
Cancer is a disease where regulation of the cell cycle
goes awry and normal cell behavior is lost. Cancer begins
when a single cell is transformed or converted from a
normal cell to a cancer cell. Often this is because of a
change in function of one of several genes that normally
function to control growth. Once these crucial cell cycle
genes start behaving abnormally, cancer cells start to
proliferate wildly by repeated, uncontrolled mitosis (9,
10).
If cell division is understood completely, it might be
possible to control many forms of cancer. Basically, the
cell cycle is the "program" for cell growth and cell division
(proliferation). There are 4 broad phases of the cell cycle:
G1 (and G0), S, G2, and M. The G1 (Gap 1) phase is
characterized by gene expression and protein synthesis.
This is really the only part of the cell cycle regulated
primarily by extracellular stimuli (like mitogens and
adhesion). Anyway, this phase enables the cell to grow
and to produce all the necessary proteins for DNA
synthesis. It primes the cell to enter the next phase: The
S (Synthesis) phase. During this phase, DNA is
synthesized. DNA is synthesized only during the S phase
between G1 and G2. During the G2 phase, the cell again
undergoes growth and protein synthesis; it needs enough
proteins for 2 cells, priming it to be able to divide. Once
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this is complete (by the way, there are many
"checkpoints" along the way), the cell finally enters the
fourth and final phase of the cell cycle: the M (Mitosis)
phase. During the M phase, the cell splits apart (called
cytokinesis) into two daughter cells. Following mitosis,
the daughter cells may re-enter the G1 phase, or proceed
to a 5th phase called "G0", where growth and replication
stops. Cells in G0 are said to be "quiescent". G0 cells may
eventually re-enter G1 or perhaps die (11). (Figure 4).

Figure 4.

Phases of the cell cycle.

Cancer cells escape from the controls on cell division,
and the action mechanism of anti-neoplastic drugs is
based on the stopping of uncontrolled cells at any one
stage of the cell cycle (9). It is very important that the
action mechanism of the anti-neoplastic drugs is known
for the treatment of cancer cells.
We therefore set out to investigate the effects of
MTX, a drug that has been in use clinically in the
antimetabolic group of drugs, and Vepesid, a semisynthetic derivative of podophylotoxin obtained from the
plant Podophylum peltatum, on the cells of HEp-2 cell
culture isolated from human laryngeal cancer, in the light
of the above. With this objective, we investigated the
effects of varying concentrations of these two agents on
both the morphology and cell cycle parameters (G1, S, G2,
and PI) of the HEp-2 cells.
In recent years, new drugs in clinical practice continue
to emerge in the field of chemotherapy every passing day.
Most of the drugs, although known to have toxic effects,
have succeeded in gaining clinical use. MTX and Vepesid
are the most important drugs among these antineoplastic
190

agents. MTX, which has been in use for a long time in
cancer chemotherapy as an anti-neoplastic agent,
continues to be employed widely in the various fields of
oncology (2, 12, 13). Vepesid is an antineoplastic drug
that is produced as the semi-synthetic derivative of
podophylotoxin. Although its biochemical mechanism is
not well understood, it has effects similar to those of
etoposide and tenoposide. Etoposide and tenoposide both
block the cell cycle in two specific places: they block the
phase between the last division and the start of DNA
replication (the G1 phase) and they block the replication
of DNA (the S phase). However, researchers do not fully
understand of how the compounds do this. Vepesid at low
concentrations blocks growing cells at the S and G2
phases of the cell cycle, and at higher concentrations
blocks cells at the G2 phase (1, 7, 8, 14, 15, 16).
Whilst the flow cytometric analysis of the control,
which was observed not to exhibit any pathologic
morphological changes, revealed most of the cells to be in
the G2 phase in the media containing MTX, a small
proportion of the cells were observed to have passed into
the G2 phase where synthesis of cellular components
necessary for mitotic cell division takes place, with the
majority of them being blocked at the S phase where
replication of the DNA genome was observed to take place.
In the cultures that contained Vepesid, most of the cells,
unlike those of the MTX medium, were found to be in the
G1 phase where the cellular components necessary for the
synthesis of the DNA genome occur, and only a small
proportion of the cells in the S and G2 phases. With cells in
culture under normal conditions, as in the control group,
most of the cells are expected to be in the G2 phase. In
contrast, however, for cells from the media with MTX, the
number of cells that were able to pass into the G2 phase
was found to be exactly 4 times lower than in the control
group, whereas those of the Vepesid group were exactly 8
times lower than those of the control group.
In this study, where similar concentrations of each
antineoplastic agent were used, Vepesid was clearly seen
to be more potent than MTX on the laryngeal cancer cells.
These effects are also seen clearly in Figure 2 in which the
proliferative indices of the two drugs are shown. Whilst
the cells from the control group were found to have a PI
close to 96%, that of cells from the culture media
containing MTX was found to be lower (approximately
24%) whereas that of the cells from the Vepesid media
was the lowest (12%).

N. DURAN, A.M. ALLAHVERD‹YEV, S. ÇET‹NER

In studies with MTX, which is widely used nowadays
in the treatment of leukemia and several other tumors,
Huang et al. (17) reported that MTX lead to a reduction
in the level of ribonucleotide reductase, which plays an
important role in the synthesis and repair of DNA and is
also an important regulator of cell cycle activity.
Huschtcha et al. also showed MTX to induce
morphological changes in cancer cells and also bring
about changes that lead to inhibition of DNA synthesis
within 48 hours (18).
In our study, however, we found that, like in the two
above-mentioned studies, MTX induced significant
pathological changes, and stopped the cells from
proliferating by inhibiting the synthesis of DNA at the S
(76%) and G2 (24%) phases.
Concerning the effect of Vepesid on cells under in
vitro conditions, Chatterjee et al. (19) reported that it
stops proliferation of prostate cancer cells by inhibiting
their growth at the G1 phase of the cell cycle. Bonelli et
al. (7) investigated the effect of Vepesid on the L 929 cell
series and found Vepesid to reduce DNA synthesis,
thereby resulting in an imbalance in the cell protein/DNA
ratio of the cells. They also showed that it blocks cells at
the S and G2 phases of the cell cycle. Pellicciari et al. (16)

reported that the phase in which Vepesid will inhibit cell
division depended on the cell type and concentration of
the drug employed. In our study, Vepesid was seen to
more effective than MTX at the same concentrations on
the HEp-2 cells within 48 hours and also brought about
significant cytopathological changes. In the flow
cytometric analysis, a larger proportion of the cell division
was found to have been inhibited at the G1 (86%) and S
(12%) phases. In one of the studies involving Vepesid,
quite unlike our results, Bonelli et al. found Vepesid to
inhibit the cell cycle at both the S and G2 phases on an L
929 cell series. Chatterjee et al., in their study with
prostate cancer cells, found the cells to be inhibited at the
G1 phase, similar to our results.
In the present study, whilst MTX was seen to block
cell division of the HEp-2 cells derived from human
laryngeal cancer at the S and G2 phases, Vepesid was
found to do so at the G1 phase. In comparison of the
cytopathological changes induced by these two different
drugs of different grouping, Vepesid was found to be
more effective than MTX. From these results, the
mechanism of action of MTX and Vepesid can be seen to
vary with the cell type as well as the concentration of the
drug.

References
1.

Kayaalp SO: T›bbi Farmakoloji Birinci
Cilt. Hacettepe Tafl Kitapç›l›k Ltd. fiti.
Ankara, 1998, 352-365.

2.

Huennekens FM. The methotrexate
story: a paradigm for development of
cancer chemotherapeutic agents. Adv
Enzyme Regul 34: 397-419, 1994.

3.

4.

5.

Kamen B. Folate and antifolate
pharmocology. Semin oncol 24-5: 1839, 1997.

6.

Serrano EE, Schimke RT. Flow
cytometric analysis of mammalian glial
cultures treated with methotrexate. Glia
3; 6: 539-49, 1993.

7.

Bonelli G, Sacchi MC, Barbiero G,
Duranti F, Goglio G. Apoptosis of L 929
cells by etoposide: a quantitative and
kinetic approach. Exp Cell Res 228; 2:
292-305, 1996.

8.

Ohisho Y, Fujiwara K, Kohno I. Effect of
the exposure dose of etoposide on the
cell growth and cell kinetic of human
ovarian cancer cells. Cancer Chemoter
Pharmacol 38; 2: 141-6, 1996.
May KP, Mercill D, McDermott MT,
West SG. The effect of methotrexate on
mouse bone cells in culture. Arthritis
Rheum 39; 3: 489-94, 1996.

9.

Chang AY, Kim K, Boucher H, Bonomi
P. A randomized phase 2 trial of
echinomycin trimetrexate, cisplatin plus
etoposide in patients with metastatic
non small cell lung carcinoma; an
eastern cooperative oncology group
study. Cancer 82; 2: 292-300, 1998.
Beijersbergen RL, Bernards R. Cell cycle
regulation by the retinoblastoma family
of growth inhibitory proteins: Reviews
on Cancer Biochem Biophys Acta 1287:
103-120, 1996.

10.

Bernards R. E2F: A nodal point in cell
cycle regulation BBA. Reviews on
Cancer 1333: M33-M40, 1997.

11.

Adams RLP: Laboratory Techniques in
biochemical and molecular biology, cell
culture for biochemists. Netherlands
1980, pp: 115-136, 174, 235

12.

Bruce-Gregorios JH, Agarwal RP,
Oracion A, Ramirez A, Lin L. Effects of
methotrexate on RNA and purine
synthesis of astrocytes in primary
culture. J Neuropathol Exp Neurol 50;
6: 770-8, 1991.

13.

Wöltgens JH, Lyaruu DM, Bronckers AL,
Van Duin MA, Bervoets TJ. Effect of
methotrexate on cell proliferation in
developing hamster molar tooth germs
in vitro. Eur J Oral Sci 106; 1: 156-9,
1998.

191

Flow Cytometric Analysis of the Effects of Methotrexate and Vepesid on the HEp-2 Cell Cycle

14.

15.

192

Mareel MM, Dragonetti CH, De Bruyne
GK,
Van
Cauwenberge
RM.
Glycosylated
podophyllotoxin
congeners: loss of microtubule
inhibition and permission of invasion in
vitro. J Natl Cancer Inst 69; 6: 136774, 1982.
Osmak M. Collateral resistance or
sensitivity of human larynx carcinoma
Hep-2
cells
resistant
to
cisdichlorodiammineplatinum (II) or
vincristine sulfate. Neoplasma 39; 3:
197-202, 1992.

16.

Pellicciari C, Bottone MG, Schoack K.
Etoposide at different concentrations
may open different apoptotic path ways
in thymocytes. Eur J Histochem 40; 4:
289-98, 1996.

17.

Huang A, Fan H, Taylor WR, Wright JA.
Ribonucleotide reductase R 2 gene
expression and changes in drug
sensivity and genome stability. Cancer
Res 57-21: 4876-81, 1997.

18.

Huschtscha LI, Bartier WA, Ross CE.
Characteristics of cancer cell death after
exposure to cytotoxic drug in vitro. Br J
Cancer 73; 1: 54-60, 1996.

19.

Chatterjee D, Wyche JJ, Pantazis P.
Induction of apoptosis in malignant and
camptothecin-resistant human cells.
Ann N Y Acad Sci 803: 143-56, 1996.

